UPEI-300

a combination of edavarone and lipoic acid with neuroprotective activity

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Stroke (Strokes) 02/21/2014 - "The current investigation was designed to determine if a newly synthesized co-drug consisting of lipoic acid and edaravone, named UPEI-300, could produce neuroprotection in in vitro and/or an in vivo rodent model of stroke. "
2.	Ischemia 02/21/2014 - "Significant neuroprotection was also observed when UPEI-300 (1.0 mg/kg) was injected during the 30 min period of ischemia as well as up to 60 min following the start of reperfusion. " 02/21/2014 - "UPEI-300, a conjugate of lipoic acid and edaravone, mediates neuroprotection in ischemia/reperfusion."
3.	Infarction (Infarctions) 02/21/2014 - "Pre-administration of UPEI-300 dose-dependently decreased infarct volume. "